nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—Protein Kinase Inhibitors—Temsirolimus—kidney cancer	0.126	0.291	CiPCiCtD
Pazopanib—Protein Kinase Inhibitors—Sunitinib—kidney cancer	0.0957	0.221	CiPCiCtD
Pazopanib—Cytochrome P450 2D6 Inhibitors—Everolimus—kidney cancer	0.0913	0.21	CiPCiCtD
Pazopanib—Protein Kinase Inhibitors—Everolimus—kidney cancer	0.0725	0.167	CiPCiCtD
Pazopanib—FLT1—kidney cancer	0.0697	0.425	CbGaD
Pazopanib—Cytochrome P450 3A4 Inhibitors—Everolimus—kidney cancer	0.0482	0.111	CiPCiCtD
Pazopanib—KDR—kidney cancer	0.0437	0.266	CbGaD
Pazopanib—KIT—kidney cancer	0.0413	0.251	CbGaD
Pazopanib—PIP4K2C—Erlotinib—kidney cancer	0.0139	0.0524	CbGbCtD
Pazopanib—RIOK2—Sunitinib—kidney cancer	0.0126	0.0478	CbGbCtD
Pazopanib—ITK—Sunitinib—kidney cancer	0.0126	0.0478	CbGbCtD
Pazopanib—AURKC—Erlotinib—kidney cancer	0.011	0.0417	CbGbCtD
Pazopanib—ABCB1—kidney cancer	0.00951	0.0579	CbGaD
Pazopanib—STK16—Sunitinib—kidney cancer	0.00915	0.0345	CbGbCtD
Pazopanib—AURKC—Sorafenib—kidney cancer	0.00897	0.0339	CbGbCtD
Pazopanib—FLT1—Sorafenib—kidney cancer	0.00897	0.0339	CbGbCtD
Pazopanib—FLT4—Sorafenib—kidney cancer	0.0075	0.0283	CbGbCtD
Pazopanib—FGFR1—Sorafenib—kidney cancer	0.0075	0.0283	CbGbCtD
Pazopanib—AURKC—Sunitinib—kidney cancer	0.00727	0.0274	CbGbCtD
Pazopanib—FLT1—Sunitinib—kidney cancer	0.00727	0.0274	CbGbCtD
Pazopanib—KDR—Sorafenib—kidney cancer	0.00648	0.0245	CbGbCtD
Pazopanib—STK10—Erlotinib—kidney cancer	0.00633	0.0239	CbGbCtD
Pazopanib—PLK4—Sunitinib—kidney cancer	0.00608	0.023	CbGbCtD
Pazopanib—FGFR1—Sunitinib—kidney cancer	0.00608	0.023	CbGbCtD
Pazopanib—FGFR2—Sunitinib—kidney cancer	0.00608	0.023	CbGbCtD
Pazopanib—TAOK3—Sunitinib—kidney cancer	0.00608	0.023	CbGbCtD
Pazopanib—FLT4—Sunitinib—kidney cancer	0.00608	0.023	CbGbCtD
Pazopanib—MAP2K5—Erlotinib—kidney cancer	0.00576	0.0218	CbGbCtD
Pazopanib—EPHB6—Sorafenib—kidney cancer	0.00573	0.0216	CbGbCtD
Pazopanib—MAP3K19—Erlotinib—kidney cancer	0.0053	0.02	CbGbCtD
Pazopanib—MAP3K2—Sunitinib—kidney cancer	0.00525	0.0198	CbGbCtD
Pazopanib—KDR—Sunitinib—kidney cancer	0.00525	0.0198	CbGbCtD
Pazopanib—PDGFRA—Sorafenib—kidney cancer	0.00515	0.0195	CbGbCtD
Pazopanib—CSF1R—Sorafenib—kidney cancer	0.00515	0.0195	CbGbCtD
Pazopanib—STK10—Sorafenib—kidney cancer	0.00515	0.0195	CbGbCtD
Pazopanib—KIT—Sorafenib—kidney cancer	0.00515	0.0195	CbGbCtD
Pazopanib—MAP2K5—Sorafenib—kidney cancer	0.00469	0.0177	CbGbCtD
Pazopanib—PDGFRB—Sorafenib—kidney cancer	0.00469	0.0177	CbGbCtD
Pazopanib—EPHB6—Sunitinib—kidney cancer	0.00464	0.0175	CbGbCtD
Pazopanib—MAP3K19—Sorafenib—kidney cancer	0.00431	0.0163	CbGbCtD
Pazopanib—CSF1R—Sunitinib—kidney cancer	0.00417	0.0158	CbGbCtD
Pazopanib—STK10—Sunitinib—kidney cancer	0.00417	0.0158	CbGbCtD
Pazopanib—KIT—Sunitinib—kidney cancer	0.00417	0.0158	CbGbCtD
Pazopanib—PDGFRA—Sunitinib—kidney cancer	0.00417	0.0158	CbGbCtD
Pazopanib—MAP2K5—Sunitinib—kidney cancer	0.0038	0.0143	CbGbCtD
Pazopanib—PDGFRB—Sunitinib—kidney cancer	0.0038	0.0143	CbGbCtD
Pazopanib—STK10—renal vein—kidney cancer	0.00369	0.148	CbGeAlD
Pazopanib—MAP3K19—Sunitinib—kidney cancer	0.00349	0.0132	CbGbCtD
Pazopanib—STK10—renal artery—kidney cancer	0.00248	0.0996	CbGeAlD
Pazopanib—UGT1A1—Erlotinib—kidney cancer	0.0019	0.00718	CbGbCtD
Pazopanib—UGT1A1—Sorafenib—kidney cancer	0.00155	0.00584	CbGbCtD
Pazopanib—ABCG2—Dactinomycin—kidney cancer	0.00134	0.00506	CbGbCtD
Pazopanib—ABCG2—Erlotinib—kidney cancer	0.00105	0.00395	CbGbCtD
Pazopanib—ABCB1—Temsirolimus—kidney cancer	0.00101	0.0038	CbGbCtD
Pazopanib—ABCG2—Paclitaxel—kidney cancer	0.000957	0.00362	CbGbCtD
Pazopanib—CYP2D6—Temsirolimus—kidney cancer	0.000948	0.00358	CbGbCtD
Pazopanib—CYP3A4—Everolimus—kidney cancer	0.000892	0.00337	CbGbCtD
Pazopanib—ABCG2—Sorafenib—kidney cancer	0.00085	0.00321	CbGbCtD
Pazopanib—ABCG2—Vincristine—kidney cancer	0.000826	0.00312	CbGbCtD
Pazopanib—ABCG2—Sunitinib—kidney cancer	0.000689	0.0026	CbGbCtD
Pazopanib—UGT1A1—urine—kidney cancer	0.000657	0.0264	CbGeAlD
Pazopanib—CYP3A4—Temsirolimus—kidney cancer	0.000603	0.00228	CbGbCtD
Pazopanib—CYP2C8—Erlotinib—kidney cancer	0.000557	0.0021	CbGbCtD
Pazopanib—ABCG2—Doxorubicin—kidney cancer	0.000516	0.00195	CbGbCtD
Pazopanib—CYP2C8—Paclitaxel—kidney cancer	0.00051	0.00193	CbGbCtD
Pazopanib—ABCB1—Dactinomycin—kidney cancer	0.000483	0.00183	CbGbCtD
Pazopanib—CYP2C8—Sorafenib—kidney cancer	0.000453	0.00171	CbGbCtD
Pazopanib—CYP1A2—Erlotinib—kidney cancer	0.000431	0.00163	CbGbCtD
Pazopanib—SH2B3—nephron tubule—kidney cancer	0.000389	0.0156	CbGeAlD
Pazopanib—ABCB1—Gemcitabine—kidney cancer	0.000382	0.00144	CbGbCtD
Pazopanib—ABCB1—Erlotinib—kidney cancer	0.000377	0.00142	CbGbCtD
Pazopanib—TAOK1—renal system—kidney cancer	0.000376	0.0151	CbGeAlD
Pazopanib—CYP2D6—Erlotinib—kidney cancer	0.000355	0.00134	CbGbCtD
Pazopanib—TAOK1—cortex of kidney—kidney cancer	0.000354	0.0142	CbGeAlD
Pazopanib—CYP1A2—Sorafenib—kidney cancer	0.000351	0.00132	CbGbCtD
Pazopanib—ABCB1—Paclitaxel—kidney cancer	0.000345	0.0013	CbGbCtD
Pazopanib—TAOK1—gonad—kidney cancer	0.000337	0.0135	CbGeAlD
Pazopanib—SH2B3—cortex of kidney—kidney cancer	0.000333	0.0134	CbGeAlD
Pazopanib—RIOK2—nephron tubule—kidney cancer	0.000326	0.0131	CbGeAlD
Pazopanib—SH2B3—cardiac atrium—kidney cancer	0.000317	0.0127	CbGeAlD
Pazopanib—AURKC—gonad—kidney cancer	0.000312	0.0125	CbGeAlD
Pazopanib—ABCB1—Sorafenib—kidney cancer	0.000307	0.00116	CbGbCtD
Pazopanib—ABCB1—Vinblastine—kidney cancer	0.000303	0.00114	CbGbCtD
Pazopanib—ABCB1—Vincristine—kidney cancer	0.000298	0.00112	CbGbCtD
Pazopanib—FGFR3—renal system—kidney cancer	0.000296	0.0119	CbGeAlD
Pazopanib—CYP1A2—urine—kidney cancer	0.000291	0.0117	CbGeAlD
Pazopanib—CYP2D6—Sorafenib—kidney cancer	0.000289	0.00109	CbGbCtD
Pazopanib—PI4KB—nephron tubule—kidney cancer	0.000288	0.0116	CbGeAlD
Pazopanib—FGFR3—kidney—kidney cancer	0.000286	0.0115	CbGeAlD
Pazopanib—PLK4—gonad—kidney cancer	0.000286	0.0115	CbGeAlD
Pazopanib—CYP2D6—Vinblastine—kidney cancer	0.000285	0.00108	CbGbCtD
Pazopanib—RIOK2—cortex of kidney—kidney cancer	0.000279	0.0112	CbGeAlD
Pazopanib—FGFR3—cortex of kidney—kidney cancer	0.000279	0.0112	CbGeAlD
Pazopanib—FGFR3—gonad—kidney cancer	0.000266	0.0107	CbGeAlD
Pazopanib—RIOK2—cardiac atrium—kidney cancer	0.000265	0.0107	CbGeAlD
Pazopanib—PI4KB—renal system—kidney cancer	0.000262	0.0105	CbGeAlD
Pazopanib—PI4KB—kidney—kidney cancer	0.000253	0.0102	CbGeAlD
Pazopanib—PIP4K2C—nephron tubule—kidney cancer	0.000253	0.0102	CbGeAlD
Pazopanib—STK36—cortex of kidney—kidney cancer	0.000251	0.0101	CbGeAlD
Pazopanib—ABCB1—Sunitinib—kidney cancer	0.000248	0.000938	CbGbCtD
Pazopanib—PI4KB—cortex of kidney—kidney cancer	0.000247	0.00991	CbGeAlD
Pazopanib—LIMK2—cortex of kidney—kidney cancer	0.000242	0.00973	CbGeAlD
Pazopanib—MAP3K2—nephron tubule—kidney cancer	0.00024	0.00963	CbGeAlD
Pazopanib—STK36—gonad—kidney cancer	0.000239	0.00958	CbGeAlD
Pazopanib—PI4KB—gonad—kidney cancer	0.000235	0.00944	CbGeAlD
Pazopanib—PI4KB—cardiac atrium—kidney cancer	0.000235	0.00942	CbGeAlD
Pazopanib—LIMK2—gonad—kidney cancer	0.000231	0.00926	CbGeAlD
Pazopanib—CYP3A4—Erlotinib—kidney cancer	0.000226	0.000853	CbGbCtD
Pazopanib—FGF1—nephron tubule—kidney cancer	0.000226	0.00907	CbGeAlD
Pazopanib—FLT4—cortex of kidney—kidney cancer	0.000218	0.00874	CbGeAlD
Pazopanib—PIP4K2C—cortex of kidney—kidney cancer	0.000216	0.00869	CbGeAlD
Pazopanib—FGFR1—cortex of kidney—kidney cancer	0.000215	0.00862	CbGeAlD
Pazopanib—CYP3A4—urine—kidney cancer	0.00021	0.00845	CbGeAlD
Pazopanib—CYP2D6—urine—kidney cancer	0.000207	0.00832	CbGeAlD
Pazopanib—CYP3A4—Paclitaxel—kidney cancer	0.000207	0.000781	CbGbCtD
Pazopanib—PIP4K2C—gonad—kidney cancer	0.000206	0.00828	CbGeAlD
Pazopanib—PIP4K2C—cardiac atrium—kidney cancer	0.000206	0.00827	CbGeAlD
Pazopanib—FGF1—renal system—kidney cancer	0.000205	0.00825	CbGeAlD
Pazopanib—FGFR1—cardiac atrium—kidney cancer	0.000204	0.0082	CbGeAlD
Pazopanib—PLK4—Epirubicin—Doxorubicin—kidney cancer	0.0002	0.5	CbGdCrCtD
Pazopanib—PLK4—Idarubicin—Doxorubicin—kidney cancer	0.0002	0.5	CbGdCrCtD
Pazopanib—FGF1—kidney—kidney cancer	0.000198	0.00797	CbGeAlD
Pazopanib—FLT1—nephron tubule—kidney cancer	0.000198	0.00794	CbGeAlD
Pazopanib—MAP3K2—gonad—kidney cancer	0.000195	0.00785	CbGeAlD
Pazopanib—FGFR2—renal system—kidney cancer	0.000194	0.00779	CbGeAlD
Pazopanib—FGF1—cortex of kidney—kidney cancer	0.000193	0.00776	CbGeAlD
Pazopanib—FGFR2—kidney—kidney cancer	0.000187	0.00753	CbGeAlD
Pazopanib—TAOK3—nephron tubule—kidney cancer	0.000186	0.00749	CbGeAlD
Pazopanib—ABCB1—Doxorubicin—kidney cancer	0.000186	0.000703	CbGbCtD
Pazopanib—FGF1—cardiac atrium—kidney cancer	0.000184	0.00738	CbGeAlD
Pazopanib—CYP3A4—Sorafenib—kidney cancer	0.000184	0.000694	CbGbCtD
Pazopanib—CYP3A4—Vinblastine—kidney cancer	0.000181	0.000685	CbGbCtD
Pazopanib—FLT1—renal system—kidney cancer	0.00018	0.00722	CbGeAlD
Pazopanib—CYP3A4—Vincristine—kidney cancer	0.000178	0.000674	CbGbCtD
Pazopanib—CYP2D6—Doxorubicin—kidney cancer	0.000175	0.000662	CbGbCtD
Pazopanib—FLT1—kidney—kidney cancer	0.000174	0.00698	CbGeAlD
Pazopanib—STK10—renal system—kidney cancer	0.00017	0.00683	CbGeAlD
Pazopanib—TAOK3—renal system—kidney cancer	0.000169	0.00681	CbGeAlD
Pazopanib—FLT1—cortex of kidney—kidney cancer	0.000169	0.0068	CbGeAlD
Pazopanib—PDGFRA—renal system—kidney cancer	0.000168	0.00676	CbGeAlD
Pazopanib—EPHB6—cortex of kidney—kidney cancer	0.000167	0.00672	CbGeAlD
Pazopanib—KDR—nephron tubule—kidney cancer	0.000167	0.00671	CbGeAlD
Pazopanib—STK10—kidney—kidney cancer	0.000164	0.00661	CbGeAlD
Pazopanib—TAOK3—kidney—kidney cancer	0.000164	0.00658	CbGeAlD
Pazopanib—FLT1—gonad—kidney cancer	0.000161	0.00647	CbGeAlD
Pazopanib—FLT1—cardiac atrium—kidney cancer	0.000161	0.00646	CbGeAlD
Pazopanib—UGT1A1—renal system—kidney cancer	0.000161	0.00645	CbGeAlD
Pazopanib—TAOK3—cortex of kidney—kidney cancer	0.00016	0.00641	CbGeAlD
Pazopanib—EPHB6—cardiac atrium—kidney cancer	0.000159	0.00639	CbGeAlD
Pazopanib—Rilpivirine—ABCB1—kidney cancer	0.000158	1	CrCbGaD
Pazopanib—UGT1A1—kidney—kidney cancer	0.000155	0.00624	CbGeAlD
Pazopanib—STK10—gonad—kidney cancer	0.000153	0.00613	CbGeAlD
Pazopanib—KDR—renal system—kidney cancer	0.000152	0.0061	CbGeAlD
Pazopanib—TAOK3—cardiac atrium—kidney cancer	0.000152	0.0061	CbGeAlD
Pazopanib—PDGFRA—gonad—kidney cancer	0.000151	0.00607	CbGeAlD
Pazopanib—CYP3A4—Sunitinib—kidney cancer	0.000149	0.000562	CbGbCtD
Pazopanib—KIT—nephron tubule—kidney cancer	0.000148	0.00595	CbGeAlD
Pazopanib—KDR—kidney—kidney cancer	0.000147	0.0059	CbGeAlD
Pazopanib—KDR—cortex of kidney—kidney cancer	0.000143	0.00574	CbGeAlD
Pazopanib—MAP2K5—cortex of kidney—kidney cancer	0.000143	0.00574	CbGeAlD
Pazopanib—KDR—cardiac atrium—kidney cancer	0.000136	0.00546	CbGeAlD
Pazopanib—MAP2K5—cardiac atrium—kidney cancer	0.000136	0.00546	CbGeAlD
Pazopanib—KIT—renal system—kidney cancer	0.000135	0.00541	CbGeAlD
Pazopanib—SLCO1B1—renal system—kidney cancer	0.000134	0.00537	CbGeAlD
Pazopanib—CSF1R—gonad—kidney cancer	0.000133	0.00534	CbGeAlD
Pazopanib—CSF1R—cardiac atrium—kidney cancer	0.000133	0.00533	CbGeAlD
Pazopanib—PDGFRB—renal system—kidney cancer	0.000132	0.00528	CbGeAlD
Pazopanib—KIT—kidney—kidney cancer	0.00013	0.00523	CbGeAlD
Pazopanib—SLCO1B1—kidney—kidney cancer	0.000129	0.00519	CbGeAlD
Pazopanib—PDGFRB—kidney—kidney cancer	0.000127	0.00511	CbGeAlD
Pazopanib—KIT—cortex of kidney—kidney cancer	0.000127	0.00509	CbGeAlD
Pazopanib—PDGFRB—cortex of kidney—kidney cancer	0.000124	0.00497	CbGeAlD
Pazopanib—KIT—gonad—kidney cancer	0.000121	0.00485	CbGeAlD
Pazopanib—PDGFRB—gonad—kidney cancer	0.000118	0.00474	CbGeAlD
Pazopanib—PDGFRB—cardiac atrium—kidney cancer	0.000118	0.00473	CbGeAlD
Pazopanib—CYP3A4—Doxorubicin—kidney cancer	0.000111	0.000421	CbGbCtD
Pazopanib—ABCG2—nephron tubule—kidney cancer	8.13e-05	0.00327	CbGeAlD
Pazopanib—CYP2C8—renal system—kidney cancer	7.6e-05	0.00305	CbGeAlD
Pazopanib—CYP2C8—kidney—kidney cancer	7.35e-05	0.00295	CbGeAlD
Pazopanib—CYP1A2—renal system—kidney cancer	7.11e-05	0.00286	CbGeAlD
Pazopanib—CYP3A4—renal system—kidney cancer	5.15e-05	0.00207	CbGeAlD
Pazopanib—CYP2D6—renal system—kidney cancer	5.07e-05	0.00203	CbGeAlD
Pazopanib—CYP3A4—kidney—kidney cancer	4.98e-05	0.002	CbGeAlD
Pazopanib—CYP2D6—kidney—kidney cancer	4.9e-05	0.00197	CbGeAlD
Pazopanib—ABCB1—nephron tubule—kidney cancer	4.01e-05	0.00161	CbGeAlD
Pazopanib—ABCB1—renal system—kidney cancer	3.64e-05	0.00146	CbGeAlD
Pazopanib—ABCB1—kidney—kidney cancer	3.52e-05	0.00141	CbGeAlD
Pazopanib—ABCB1—cortex of kidney—kidney cancer	3.43e-05	0.00138	CbGeAlD
Pazopanib—ABCB1—gonad—kidney cancer	3.27e-05	0.00131	CbGeAlD
Pazopanib—Anaemia—Paclitaxel—kidney cancer	1.46e-05	0.000228	CcSEcCtD
Pazopanib—Urethral disorder—Capecitabine—kidney cancer	1.46e-05	0.000228	CcSEcCtD
Pazopanib—Paraesthesia—Vincristine—kidney cancer	1.46e-05	0.000227	CcSEcCtD
Pazopanib—Rash—Everolimus—kidney cancer	1.45e-05	0.000226	CcSEcCtD
Pazopanib—Dermatitis—Everolimus—kidney cancer	1.45e-05	0.000226	CcSEcCtD
Pazopanib—Headache—Vinblastine—kidney cancer	1.44e-05	0.000225	CcSEcCtD
Pazopanib—Headache—Everolimus—kidney cancer	1.44e-05	0.000224	CcSEcCtD
Pazopanib—Abdominal pain—Dactinomycin—kidney cancer	1.44e-05	0.000224	CcSEcCtD
Pazopanib—Asthenia—Sorafenib—kidney cancer	1.43e-05	0.000223	CcSEcCtD
Pazopanib—Cardiac failure—Doxorubicin—kidney cancer	1.42e-05	0.000222	CcSEcCtD
Pazopanib—Syncope—Paclitaxel—kidney cancer	1.42e-05	0.000221	CcSEcCtD
Pazopanib—Lethargy—Doxorubicin—kidney cancer	1.42e-05	0.000221	CcSEcCtD
Pazopanib—Cerebrovascular accident—Doxorubicin—kidney cancer	1.42e-05	0.000221	CcSEcCtD
Pazopanib—Leukopenia—Paclitaxel—kidney cancer	1.41e-05	0.000221	CcSEcCtD
Pazopanib—Decreased appetite—Vincristine—kidney cancer	1.41e-05	0.00022	CcSEcCtD
Pazopanib—Pruritus—Sorafenib—kidney cancer	1.41e-05	0.00022	CcSEcCtD
Pazopanib—Vomiting—Erlotinib—kidney cancer	1.41e-05	0.00022	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Gemcitabine—kidney cancer	1.4e-05	0.000219	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Vincristine—kidney cancer	1.4e-05	0.000219	CcSEcCtD
Pazopanib—Fatigue—Vincristine—kidney cancer	1.4e-05	0.000218	CcSEcCtD
Pazopanib—Rash—Erlotinib—kidney cancer	1.4e-05	0.000218	CcSEcCtD
Pazopanib—Dermatitis—Erlotinib—kidney cancer	1.4e-05	0.000218	CcSEcCtD
Pazopanib—Hyponatraemia—Doxorubicin—kidney cancer	1.39e-05	0.000217	CcSEcCtD
Pazopanib—Insomnia—Gemcitabine—kidney cancer	1.39e-05	0.000217	CcSEcCtD
Pazopanib—Eye disorder—Capecitabine—kidney cancer	1.39e-05	0.000217	CcSEcCtD
Pazopanib—Headache—Erlotinib—kidney cancer	1.39e-05	0.000217	CcSEcCtD
Pazopanib—Loss of consciousness—Paclitaxel—kidney cancer	1.39e-05	0.000217	CcSEcCtD
Pazopanib—Pain—Vincristine—kidney cancer	1.39e-05	0.000216	CcSEcCtD
Pazopanib—Gastrointestinal haemorrhage—Doxorubicin—kidney cancer	1.39e-05	0.000216	CcSEcCtD
Pazopanib—Paraesthesia—Gemcitabine—kidney cancer	1.38e-05	0.000216	CcSEcCtD
Pazopanib—Flushing—Capecitabine—kidney cancer	1.38e-05	0.000216	CcSEcCtD
Pazopanib—Cardiac disorder—Capecitabine—kidney cancer	1.38e-05	0.000216	CcSEcCtD
Pazopanib—Cough—Paclitaxel—kidney cancer	1.38e-05	0.000215	CcSEcCtD
Pazopanib—Asthenia—Sunitinib—kidney cancer	1.38e-05	0.000215	CcSEcCtD
Pazopanib—Dyspnoea—Gemcitabine—kidney cancer	1.37e-05	0.000214	CcSEcCtD
Pazopanib—Nausea—Vinblastine—kidney cancer	1.37e-05	0.000214	CcSEcCtD
Pazopanib—Somnolence—Gemcitabine—kidney cancer	1.37e-05	0.000213	CcSEcCtD
Pazopanib—Nausea—Everolimus—kidney cancer	1.36e-05	0.000213	CcSEcCtD
Pazopanib—Diarrhoea—Sorafenib—kidney cancer	1.36e-05	0.000213	CcSEcCtD
Pazopanib—Hypertension—Paclitaxel—kidney cancer	1.36e-05	0.000213	CcSEcCtD
Pazopanib—Pruritus—Sunitinib—kidney cancer	1.36e-05	0.000212	CcSEcCtD
Pazopanib—Angiopathy—Capecitabine—kidney cancer	1.35e-05	0.000211	CcSEcCtD
Pazopanib—Arthralgia—Paclitaxel—kidney cancer	1.34e-05	0.00021	CcSEcCtD
Pazopanib—Chest pain—Paclitaxel—kidney cancer	1.34e-05	0.00021	CcSEcCtD
Pazopanib—Myalgia—Paclitaxel—kidney cancer	1.34e-05	0.00021	CcSEcCtD
Pazopanib—Mediastinal disorder—Capecitabine—kidney cancer	1.34e-05	0.000209	CcSEcCtD
Pazopanib—Face oedema—Doxorubicin—kidney cancer	1.34e-05	0.000209	CcSEcCtD
Pazopanib—Decreased appetite—Gemcitabine—kidney cancer	1.34e-05	0.000209	CcSEcCtD
Pazopanib—Chills—Capecitabine—kidney cancer	1.34e-05	0.000208	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	1.33e-05	0.000208	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Gemcitabine—kidney cancer	1.33e-05	0.000207	CcSEcCtD
Pazopanib—Fatigue—Gemcitabine—kidney cancer	1.33e-05	0.000207	CcSEcCtD
Pazopanib—Gastrointestinal pain—Vincristine—kidney cancer	1.33e-05	0.000207	CcSEcCtD
Pazopanib—Dizziness—Sorafenib—kidney cancer	1.32e-05	0.000206	CcSEcCtD
Pazopanib—Pain—Gemcitabine—kidney cancer	1.32e-05	0.000205	CcSEcCtD
Pazopanib—Nausea—Erlotinib—kidney cancer	1.32e-05	0.000205	CcSEcCtD
Pazopanib—Alopecia—Capecitabine—kidney cancer	1.32e-05	0.000205	CcSEcCtD
Pazopanib—Dry mouth—Paclitaxel—kidney cancer	1.31e-05	0.000205	CcSEcCtD
Pazopanib—Diarrhoea—Sunitinib—kidney cancer	1.31e-05	0.000205	CcSEcCtD
Pazopanib—Mental disorder—Capecitabine—kidney cancer	1.3e-05	0.000203	CcSEcCtD
Pazopanib—Asthenia—Dactinomycin—kidney cancer	1.3e-05	0.000203	CcSEcCtD
Pazopanib—Blood creatinine increased—Doxorubicin—kidney cancer	1.3e-05	0.000203	CcSEcCtD
Pazopanib—Malnutrition—Capecitabine—kidney cancer	1.3e-05	0.000202	CcSEcCtD
Pazopanib—Erythema—Capecitabine—kidney cancer	1.3e-05	0.000202	CcSEcCtD
Pazopanib—Dehydration—Doxorubicin—kidney cancer	1.29e-05	0.000201	CcSEcCtD
Pazopanib—Oedema—Paclitaxel—kidney cancer	1.29e-05	0.000201	CcSEcCtD
Pazopanib—Abdominal pain—Vincristine—kidney cancer	1.28e-05	0.0002	CcSEcCtD
Pazopanib—Liver function test abnormal—Doxorubicin—kidney cancer	1.28e-05	0.0002	CcSEcCtD
Pazopanib—Infection—Paclitaxel—kidney cancer	1.28e-05	0.0002	CcSEcCtD
Pazopanib—Flatulence—Capecitabine—kidney cancer	1.28e-05	0.000199	CcSEcCtD
Pazopanib—Dry skin—Doxorubicin—kidney cancer	1.27e-05	0.000198	CcSEcCtD
Pazopanib—Dysgeusia—Capecitabine—kidney cancer	1.27e-05	0.000198	CcSEcCtD
Pazopanib—Dizziness—Sunitinib—kidney cancer	1.27e-05	0.000198	CcSEcCtD
Pazopanib—Shock—Paclitaxel—kidney cancer	1.27e-05	0.000198	CcSEcCtD
Pazopanib—Vomiting—Sorafenib—kidney cancer	1.27e-05	0.000198	CcSEcCtD
Pazopanib—Abdominal pain upper—Doxorubicin—kidney cancer	1.27e-05	0.000198	CcSEcCtD
Pazopanib—Nervous system disorder—Paclitaxel—kidney cancer	1.26e-05	0.000197	CcSEcCtD
Pazopanib—Thrombocytopenia—Paclitaxel—kidney cancer	1.26e-05	0.000197	CcSEcCtD
Pazopanib—Rash—Sorafenib—kidney cancer	1.26e-05	0.000196	CcSEcCtD
Pazopanib—Dermatitis—Sorafenib—kidney cancer	1.26e-05	0.000196	CcSEcCtD
Pazopanib—Breast disorder—Doxorubicin—kidney cancer	1.25e-05	0.000196	CcSEcCtD
Pazopanib—Skin disorder—Paclitaxel—kidney cancer	1.25e-05	0.000195	CcSEcCtD
Pazopanib—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	1.25e-05	0.000195	CcSEcCtD
Pazopanib—Headache—Sorafenib—kidney cancer	1.25e-05	0.000195	CcSEcCtD
Pazopanib—Muscle spasms—Capecitabine—kidney cancer	1.25e-05	0.000194	CcSEcCtD
Pazopanib—Hyperhidrosis—Paclitaxel—kidney cancer	1.25e-05	0.000194	CcSEcCtD
Pazopanib—Diarrhoea—Dactinomycin—kidney cancer	1.24e-05	0.000194	CcSEcCtD
Pazopanib—Nasopharyngitis—Doxorubicin—kidney cancer	1.24e-05	0.000194	CcSEcCtD
Pazopanib—Anorexia—Paclitaxel—kidney cancer	1.23e-05	0.000192	CcSEcCtD
Pazopanib—Alanine aminotransferase increased—Doxorubicin—kidney cancer	1.22e-05	0.000191	CcSEcCtD
Pazopanib—Vision blurred—Capecitabine—kidney cancer	1.22e-05	0.000191	CcSEcCtD
Pazopanib—Vomiting—Sunitinib—kidney cancer	1.22e-05	0.00019	CcSEcCtD
Pazopanib—Rash—Sunitinib—kidney cancer	1.21e-05	0.000189	CcSEcCtD
Pazopanib—Dermatitis—Sunitinib—kidney cancer	1.21e-05	0.000189	CcSEcCtD
Pazopanib—Abdominal distension—Doxorubicin—kidney cancer	1.21e-05	0.000188	CcSEcCtD
Pazopanib—Headache—Sunitinib—kidney cancer	1.2e-05	0.000187	CcSEcCtD
Pazopanib—Anaemia—Capecitabine—kidney cancer	1.2e-05	0.000187	CcSEcCtD
Pazopanib—Nausea—Sorafenib—kidney cancer	1.18e-05	0.000185	CcSEcCtD
Pazopanib—Pancreatitis—Doxorubicin—kidney cancer	1.18e-05	0.000183	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Paclitaxel—kidney cancer	1.17e-05	0.000183	CcSEcCtD
Pazopanib—Insomnia—Paclitaxel—kidney cancer	1.17e-05	0.000182	CcSEcCtD
Pazopanib—Asthenia—Vincristine—kidney cancer	1.16e-05	0.000182	CcSEcCtD
Pazopanib—Syncope—Capecitabine—kidney cancer	1.16e-05	0.000181	CcSEcCtD
Pazopanib—Leukopenia—Capecitabine—kidney cancer	1.16e-05	0.000181	CcSEcCtD
Pazopanib—Paraesthesia—Paclitaxel—kidney cancer	1.16e-05	0.000181	CcSEcCtD
Pazopanib—Vomiting—Dactinomycin—kidney cancer	1.15e-05	0.00018	CcSEcCtD
Pazopanib—Dyspnoea—Paclitaxel—kidney cancer	1.15e-05	0.000179	CcSEcCtD
Pazopanib—Somnolence—Paclitaxel—kidney cancer	1.15e-05	0.000179	CcSEcCtD
Pazopanib—Rash—Dactinomycin—kidney cancer	1.14e-05	0.000179	CcSEcCtD
Pazopanib—Nausea—Sunitinib—kidney cancer	1.14e-05	0.000178	CcSEcCtD
Pazopanib—Loss of consciousness—Capecitabine—kidney cancer	1.14e-05	0.000178	CcSEcCtD
Pazopanib—Dyspepsia—Paclitaxel—kidney cancer	1.13e-05	0.000177	CcSEcCtD
Pazopanib—Cough—Capecitabine—kidney cancer	1.13e-05	0.000176	CcSEcCtD
Pazopanib—Neutropenia—Doxorubicin—kidney cancer	1.12e-05	0.000175	CcSEcCtD
Pazopanib—Decreased appetite—Paclitaxel—kidney cancer	1.12e-05	0.000175	CcSEcCtD
Pazopanib—Hypertension—Capecitabine—kidney cancer	1.12e-05	0.000175	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Paclitaxel—kidney cancer	1.11e-05	0.000174	CcSEcCtD
Pazopanib—Fatigue—Paclitaxel—kidney cancer	1.11e-05	0.000173	CcSEcCtD
Pazopanib—Diarrhoea—Vincristine—kidney cancer	1.11e-05	0.000173	CcSEcCtD
Pazopanib—Asthenia—Gemcitabine—kidney cancer	1.1e-05	0.000172	CcSEcCtD
Pazopanib—Chest pain—Capecitabine—kidney cancer	1.1e-05	0.000172	CcSEcCtD
Pazopanib—Myalgia—Capecitabine—kidney cancer	1.1e-05	0.000172	CcSEcCtD
Pazopanib—Arthralgia—Capecitabine—kidney cancer	1.1e-05	0.000172	CcSEcCtD
Pazopanib—Pain—Paclitaxel—kidney cancer	1.1e-05	0.000172	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	1.1e-05	0.000171	CcSEcCtD
Pazopanib—Photosensitivity reaction—Doxorubicin—kidney cancer	1.09e-05	0.000171	CcSEcCtD
Pazopanib—Pruritus—Gemcitabine—kidney cancer	1.09e-05	0.00017	CcSEcCtD
Pazopanib—Weight decreased—Doxorubicin—kidney cancer	1.08e-05	0.000169	CcSEcCtD
Pazopanib—Dry mouth—Capecitabine—kidney cancer	1.08e-05	0.000168	CcSEcCtD
Pazopanib—Nausea—Dactinomycin—kidney cancer	1.08e-05	0.000168	CcSEcCtD
Pazopanib—Dizziness—Vincristine—kidney cancer	1.07e-05	0.000167	CcSEcCtD
Pazopanib—Infestation NOS—Doxorubicin—kidney cancer	1.07e-05	0.000167	CcSEcCtD
Pazopanib—Infestation—Doxorubicin—kidney cancer	1.07e-05	0.000167	CcSEcCtD
Pazopanib—Oedema—Capecitabine—kidney cancer	1.06e-05	0.000165	CcSEcCtD
Pazopanib—Gastrointestinal pain—Paclitaxel—kidney cancer	1.05e-05	0.000164	CcSEcCtD
Pazopanib—Diarrhoea—Gemcitabine—kidney cancer	1.05e-05	0.000164	CcSEcCtD
Pazopanib—Infection—Capecitabine—kidney cancer	1.05e-05	0.000164	CcSEcCtD
Pazopanib—Jaundice—Doxorubicin—kidney cancer	1.04e-05	0.000163	CcSEcCtD
Pazopanib—Stomatitis—Doxorubicin—kidney cancer	1.04e-05	0.000163	CcSEcCtD
Pazopanib—Shock—Capecitabine—kidney cancer	1.04e-05	0.000162	CcSEcCtD
Pazopanib—Nervous system disorder—Capecitabine—kidney cancer	1.04e-05	0.000162	CcSEcCtD
Pazopanib—Thrombocytopenia—Capecitabine—kidney cancer	1.04e-05	0.000162	CcSEcCtD
Pazopanib—Vomiting—Vincristine—kidney cancer	1.03e-05	0.000161	CcSEcCtD
Pazopanib—Skin disorder—Capecitabine—kidney cancer	1.03e-05	0.00016	CcSEcCtD
Pazopanib—Rash—Vincristine—kidney cancer	1.02e-05	0.00016	CcSEcCtD
Pazopanib—Hyperhidrosis—Capecitabine—kidney cancer	1.02e-05	0.00016	CcSEcCtD
Pazopanib—Dermatitis—Vincristine—kidney cancer	1.02e-05	0.000159	CcSEcCtD
Pazopanib—Haematuria—Doxorubicin—kidney cancer	1.02e-05	0.000159	CcSEcCtD
Pazopanib—Abdominal pain—Paclitaxel—kidney cancer	1.02e-05	0.000159	CcSEcCtD
Pazopanib—Headache—Vincristine—kidney cancer	1.02e-05	0.000159	CcSEcCtD
Pazopanib—Hepatobiliary disease—Doxorubicin—kidney cancer	1.01e-05	0.000158	CcSEcCtD
Pazopanib—Epistaxis—Doxorubicin—kidney cancer	1.01e-05	0.000157	CcSEcCtD
Pazopanib—Anorexia—Capecitabine—kidney cancer	1.01e-05	0.000157	CcSEcCtD
Pazopanib—Vomiting—Gemcitabine—kidney cancer	9.79e-06	0.000153	CcSEcCtD
Pazopanib—Bradycardia—Doxorubicin—kidney cancer	9.77e-06	0.000152	CcSEcCtD
Pazopanib—Rash—Gemcitabine—kidney cancer	9.7e-06	0.000151	CcSEcCtD
Pazopanib—Dermatitis—Gemcitabine—kidney cancer	9.7e-06	0.000151	CcSEcCtD
Pazopanib—Haemoglobin—Doxorubicin—kidney cancer	9.64e-06	0.00015	CcSEcCtD
Pazopanib—Headache—Gemcitabine—kidney cancer	9.64e-06	0.00015	CcSEcCtD
Pazopanib—Nausea—Vincristine—kidney cancer	9.64e-06	0.00015	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Capecitabine—kidney cancer	9.63e-06	0.00015	CcSEcCtD
Pazopanib—Haemorrhage—Doxorubicin—kidney cancer	9.59e-06	0.00015	CcSEcCtD
Pazopanib—Insomnia—Capecitabine—kidney cancer	9.56e-06	0.000149	CcSEcCtD
Pazopanib—Hypoaesthesia—Doxorubicin—kidney cancer	9.55e-06	0.000149	CcSEcCtD
Pazopanib—Paraesthesia—Capecitabine—kidney cancer	9.5e-06	0.000148	CcSEcCtD
Pazopanib—Urinary tract disorder—Doxorubicin—kidney cancer	9.48e-06	0.000148	CcSEcCtD
Pazopanib—Oedema peripheral—Doxorubicin—kidney cancer	9.45e-06	0.000147	CcSEcCtD
Pazopanib—Connective tissue disorder—Doxorubicin—kidney cancer	9.43e-06	0.000147	CcSEcCtD
Pazopanib—Dyspnoea—Capecitabine—kidney cancer	9.43e-06	0.000147	CcSEcCtD
Pazopanib—Urethral disorder—Doxorubicin—kidney cancer	9.41e-06	0.000147	CcSEcCtD
Pazopanib—Dyspepsia—Capecitabine—kidney cancer	9.31e-06	0.000145	CcSEcCtD
Pazopanib—Asthenia—Paclitaxel—kidney cancer	9.25e-06	0.000144	CcSEcCtD
Pazopanib—Decreased appetite—Capecitabine—kidney cancer	9.19e-06	0.000143	CcSEcCtD
Pazopanib—Nausea—Gemcitabine—kidney cancer	9.14e-06	0.000143	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Capecitabine—kidney cancer	9.13e-06	0.000142	CcSEcCtD
Pazopanib—Fatigue—Capecitabine—kidney cancer	9.12e-06	0.000142	CcSEcCtD
Pazopanib—Pruritus—Paclitaxel—kidney cancer	9.12e-06	0.000142	CcSEcCtD
Pazopanib—Pain—Capecitabine—kidney cancer	9.04e-06	0.000141	CcSEcCtD
Pazopanib—Eye disorder—Doxorubicin—kidney cancer	8.97e-06	0.00014	CcSEcCtD
Pazopanib—Flushing—Doxorubicin—kidney cancer	8.9e-06	0.000139	CcSEcCtD
Pazopanib—Cardiac disorder—Doxorubicin—kidney cancer	8.9e-06	0.000139	CcSEcCtD
Pazopanib—Diarrhoea—Paclitaxel—kidney cancer	8.82e-06	0.000138	CcSEcCtD
Pazopanib—Angiopathy—Doxorubicin—kidney cancer	8.7e-06	0.000136	CcSEcCtD
Pazopanib—Gastrointestinal pain—Capecitabine—kidney cancer	8.65e-06	0.000135	CcSEcCtD
Pazopanib—Mediastinal disorder—Doxorubicin—kidney cancer	8.65e-06	0.000135	CcSEcCtD
Pazopanib—Chills—Doxorubicin—kidney cancer	8.61e-06	0.000134	CcSEcCtD
Pazopanib—Dizziness—Paclitaxel—kidney cancer	8.52e-06	0.000133	CcSEcCtD
Pazopanib—Alopecia—Doxorubicin—kidney cancer	8.48e-06	0.000132	CcSEcCtD
Pazopanib—Mental disorder—Doxorubicin—kidney cancer	8.41e-06	0.000131	CcSEcCtD
Pazopanib—Abdominal pain—Capecitabine—kidney cancer	8.36e-06	0.00013	CcSEcCtD
Pazopanib—Erythema—Doxorubicin—kidney cancer	8.35e-06	0.00013	CcSEcCtD
Pazopanib—Malnutrition—Doxorubicin—kidney cancer	8.35e-06	0.00013	CcSEcCtD
Pazopanib—Flatulence—Doxorubicin—kidney cancer	8.23e-06	0.000128	CcSEcCtD
Pazopanib—Vomiting—Paclitaxel—kidney cancer	8.19e-06	0.000128	CcSEcCtD
Pazopanib—Dysgeusia—Doxorubicin—kidney cancer	8.18e-06	0.000128	CcSEcCtD
Pazopanib—Rash—Paclitaxel—kidney cancer	8.12e-06	0.000127	CcSEcCtD
Pazopanib—Dermatitis—Paclitaxel—kidney cancer	8.12e-06	0.000127	CcSEcCtD
Pazopanib—Headache—Paclitaxel—kidney cancer	8.07e-06	0.000126	CcSEcCtD
Pazopanib—Muscle spasms—Doxorubicin—kidney cancer	8.03e-06	0.000125	CcSEcCtD
Pazopanib—Vision blurred—Doxorubicin—kidney cancer	7.87e-06	0.000123	CcSEcCtD
Pazopanib—Anaemia—Doxorubicin—kidney cancer	7.72e-06	0.00012	CcSEcCtD
Pazopanib—Nausea—Paclitaxel—kidney cancer	7.65e-06	0.000119	CcSEcCtD
Pazopanib—Asthenia—Capecitabine—kidney cancer	7.59e-06	0.000118	CcSEcCtD
Pazopanib—Syncope—Doxorubicin—kidney cancer	7.49e-06	0.000117	CcSEcCtD
Pazopanib—Pruritus—Capecitabine—kidney cancer	7.48e-06	0.000117	CcSEcCtD
Pazopanib—Leukopenia—Doxorubicin—kidney cancer	7.48e-06	0.000117	CcSEcCtD
Pazopanib—Loss of consciousness—Doxorubicin—kidney cancer	7.34e-06	0.000115	CcSEcCtD
Pazopanib—Cough—Doxorubicin—kidney cancer	7.29e-06	0.000114	CcSEcCtD
Pazopanib—Diarrhoea—Capecitabine—kidney cancer	7.24e-06	0.000113	CcSEcCtD
Pazopanib—Hypertension—Doxorubicin—kidney cancer	7.21e-06	0.000113	CcSEcCtD
Pazopanib—Chest pain—Doxorubicin—kidney cancer	7.11e-06	0.000111	CcSEcCtD
Pazopanib—Myalgia—Doxorubicin—kidney cancer	7.11e-06	0.000111	CcSEcCtD
Pazopanib—Arthralgia—Doxorubicin—kidney cancer	7.11e-06	0.000111	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	7.06e-06	0.00011	CcSEcCtD
Pazopanib—Dizziness—Capecitabine—kidney cancer	6.99e-06	0.000109	CcSEcCtD
Pazopanib—Dry mouth—Doxorubicin—kidney cancer	6.95e-06	0.000109	CcSEcCtD
Pazopanib—Oedema—Doxorubicin—kidney cancer	6.82e-06	0.000106	CcSEcCtD
Pazopanib—Infection—Doxorubicin—kidney cancer	6.77e-06	0.000106	CcSEcCtD
Pazopanib—Vomiting—Capecitabine—kidney cancer	6.72e-06	0.000105	CcSEcCtD
Pazopanib—Shock—Doxorubicin—kidney cancer	6.71e-06	0.000105	CcSEcCtD
Pazopanib—Nervous system disorder—Doxorubicin—kidney cancer	6.68e-06	0.000104	CcSEcCtD
Pazopanib—Thrombocytopenia—Doxorubicin—kidney cancer	6.67e-06	0.000104	CcSEcCtD
Pazopanib—Rash—Capecitabine—kidney cancer	6.67e-06	0.000104	CcSEcCtD
Pazopanib—Dermatitis—Capecitabine—kidney cancer	6.66e-06	0.000104	CcSEcCtD
Pazopanib—Headache—Capecitabine—kidney cancer	6.62e-06	0.000103	CcSEcCtD
Pazopanib—Skin disorder—Doxorubicin—kidney cancer	6.62e-06	0.000103	CcSEcCtD
Pazopanib—Hyperhidrosis—Doxorubicin—kidney cancer	6.59e-06	0.000103	CcSEcCtD
Pazopanib—Anorexia—Doxorubicin—kidney cancer	6.5e-06	0.000101	CcSEcCtD
Pazopanib—Nausea—Capecitabine—kidney cancer	6.28e-06	9.8e-05	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Doxorubicin—kidney cancer	6.21e-06	9.69e-05	CcSEcCtD
Pazopanib—Insomnia—Doxorubicin—kidney cancer	6.17e-06	9.62e-05	CcSEcCtD
Pazopanib—Paraesthesia—Doxorubicin—kidney cancer	6.12e-06	9.55e-05	CcSEcCtD
Pazopanib—Dyspnoea—Doxorubicin—kidney cancer	6.08e-06	9.48e-05	CcSEcCtD
Pazopanib—Somnolence—Doxorubicin—kidney cancer	6.06e-06	9.46e-05	CcSEcCtD
Pazopanib—Dyspepsia—Doxorubicin—kidney cancer	6e-06	9.36e-05	CcSEcCtD
Pazopanib—Decreased appetite—Doxorubicin—kidney cancer	5.93e-06	9.25e-05	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Doxorubicin—kidney cancer	5.88e-06	9.18e-05	CcSEcCtD
Pazopanib—Fatigue—Doxorubicin—kidney cancer	5.88e-06	9.17e-05	CcSEcCtD
Pazopanib—Pain—Doxorubicin—kidney cancer	5.83e-06	9.1e-05	CcSEcCtD
Pazopanib—Gastrointestinal pain—Doxorubicin—kidney cancer	5.57e-06	8.7e-05	CcSEcCtD
Pazopanib—Abdominal pain—Doxorubicin—kidney cancer	5.39e-06	8.41e-05	CcSEcCtD
Pazopanib—Asthenia—Doxorubicin—kidney cancer	4.89e-06	7.63e-05	CcSEcCtD
Pazopanib—Pruritus—Doxorubicin—kidney cancer	4.82e-06	7.53e-05	CcSEcCtD
Pazopanib—Diarrhoea—Doxorubicin—kidney cancer	4.66e-06	7.28e-05	CcSEcCtD
Pazopanib—Dizziness—Doxorubicin—kidney cancer	4.51e-06	7.03e-05	CcSEcCtD
Pazopanib—Vomiting—Doxorubicin—kidney cancer	4.33e-06	6.76e-05	CcSEcCtD
Pazopanib—Rash—Doxorubicin—kidney cancer	4.3e-06	6.71e-05	CcSEcCtD
Pazopanib—Dermatitis—Doxorubicin—kidney cancer	4.29e-06	6.7e-05	CcSEcCtD
Pazopanib—Headache—Doxorubicin—kidney cancer	4.27e-06	6.66e-05	CcSEcCtD
Pazopanib—Nausea—Doxorubicin—kidney cancer	4.05e-06	6.32e-05	CcSEcCtD
Pazopanib—LCK—Disease—PTGS2—kidney cancer	5.08e-07	1.07e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—RELA—kidney cancer	5.08e-07	1.07e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—RELA—kidney cancer	5.07e-07	1.07e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—KRAS—kidney cancer	5.07e-07	1.07e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—ERBB2—kidney cancer	5.05e-07	1.06e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—VEGFA—kidney cancer	5.04e-07	1.06e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—PIK3CA—kidney cancer	5.04e-07	1.06e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—ERBB2—kidney cancer	5.04e-07	1.06e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—SLC5A5—kidney cancer	5.04e-07	1.06e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CDKN1B—kidney cancer	5.02e-07	1.06e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	5.01e-07	1.06e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	5.01e-07	1.06e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—MAPK3—kidney cancer	5.01e-07	1.06e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—MAPK3—kidney cancer	5e-07	1.05e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—MAPK1—kidney cancer	5e-07	1.05e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—MYC—kidney cancer	4.99e-07	1.05e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—MAPK1—kidney cancer	4.99e-07	1.05e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MTOR—kidney cancer	4.98e-07	1.05e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—KRAS—kidney cancer	4.98e-07	1.05e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MTOR—kidney cancer	4.97e-07	1.05e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—JUN—kidney cancer	4.97e-07	1.05e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GSTT1—kidney cancer	4.96e-07	1.05e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ACHE—kidney cancer	4.96e-07	1.05e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—PIK3CA—kidney cancer	4.95e-07	1.04e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—GSTP1—kidney cancer	4.94e-07	1.04e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CDKN1B—kidney cancer	4.93e-07	1.04e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—CTNNB1—kidney cancer	4.93e-07	1.04e-05	CbGpPWpGaD
Pazopanib—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	4.92e-07	1.04e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—IL2—kidney cancer	4.91e-07	1.03e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—MAPK1—kidney cancer	4.88e-07	1.03e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—MAPK1—kidney cancer	4.87e-07	1.03e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—SLC2A1—kidney cancer	4.86e-07	1.03e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—MYC—kidney cancer	4.86e-07	1.03e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PTGS2—kidney cancer	4.86e-07	1.02e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—IL2—kidney cancer	4.82e-07	1.02e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—CDKN1B—kidney cancer	4.82e-07	1.02e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—PTEN—kidney cancer	4.8e-07	1.01e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CCND1—kidney cancer	4.79e-07	1.01e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—JUN—kidney cancer	4.78e-07	1.01e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—MAPK3—kidney cancer	4.77e-07	1.01e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—MAPK1—kidney cancer	4.76e-07	1e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—MAPK1—kidney cancer	4.76e-07	1e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CTNNB1—kidney cancer	4.74e-07	9.99e-06	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—PIK3CA—kidney cancer	4.74e-07	9.99e-06	CbGpPWpGaD
Pazopanib—FGFR1—Disease—KRAS—kidney cancer	4.72e-07	9.95e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—MAPK3—kidney cancer	4.72e-07	9.95e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—KRAS—kidney cancer	4.71e-07	9.93e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CCND1—kidney cancer	4.7e-07	9.91e-06	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—PIK3CA—kidney cancer	4.7e-07	9.9e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—SCARB1—kidney cancer	4.69e-07	9.89e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—JUN—kidney cancer	4.69e-07	9.89e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—KIT—kidney cancer	4.69e-07	9.89e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—APC—kidney cancer	4.69e-07	9.89e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—PIK3CA—kidney cancer	4.69e-07	9.88e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—ABCB1—kidney cancer	4.68e-07	9.86e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CDKN1B—kidney cancer	4.68e-07	9.86e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CDKN1B—kidney cancer	4.66e-07	9.83e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CTNNB1—kidney cancer	4.66e-07	9.81e-06	CbGpPWpGaD
Pazopanib—FGFR2—Disease—PIK3CA—kidney cancer	4.65e-07	9.81e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PTGS1—kidney cancer	4.65e-07	9.79e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—MYC—kidney cancer	4.64e-07	9.78e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—PTEN—kidney cancer	4.62e-07	9.74e-06	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—KRAS—kidney cancer	4.61e-07	9.72e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—KRAS—kidney cancer	4.6e-07	9.69e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—MYC—kidney cancer	4.59e-07	9.68e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—RAF1—kidney cancer	4.59e-07	9.67e-06	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—TP53—kidney cancer	4.58e-07	9.66e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—IL2—kidney cancer	4.58e-07	9.65e-06	CbGpPWpGaD
Pazopanib—KIT—Disease—PIK3CA—kidney cancer	4.57e-07	9.63e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—RELA—kidney cancer	4.57e-07	9.62e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—IL2—kidney cancer	4.56e-07	9.62e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PSMD7—kidney cancer	4.56e-07	9.6e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—CTNNB1—kidney cancer	4.55e-07	9.59e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—GSTM1—kidney cancer	4.54e-07	9.57e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—MAPK1—kidney cancer	4.54e-07	9.57e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—ERBB2—kidney cancer	4.54e-07	9.56e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—PTEN—kidney cancer	4.54e-07	9.56e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CRABP1—kidney cancer	4.51e-07	9.51e-06	CbGpPWpGaD
Pazopanib—LYN—Immune System—KRAS—kidney cancer	4.5e-07	9.48e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—KRAS—kidney cancer	4.49e-07	9.47e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—MAPK1—kidney cancer	4.49e-07	9.47e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—RAF1—kidney cancer	4.49e-07	9.47e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MTOR—kidney cancer	4.48e-07	9.44e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—RELA—kidney cancer	4.47e-07	9.42e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—POMC—kidney cancer	4.46e-07	9.41e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CCND1—kidney cancer	4.46e-07	9.4e-06	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PTGS2—kidney cancer	4.46e-07	9.39e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—JUN—kidney cancer	4.45e-07	9.38e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CCND1—kidney cancer	4.45e-07	9.38e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—ERBB2—kidney cancer	4.44e-07	9.36e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—JUN—kidney cancer	4.44e-07	9.36e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—PTEN—kidney cancer	4.43e-07	9.35e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CTNNB1—kidney cancer	4.42e-07	9.31e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—BRAF—kidney cancer	4.41e-07	9.29e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CTNNB1—kidney cancer	4.41e-07	9.29e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MTOR—kidney cancer	4.38e-07	9.24e-06	CbGpPWpGaD
Pazopanib—FGFR1—Disease—PIK3CA—kidney cancer	4.34e-07	9.14e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—PIK3CA—kidney cancer	4.33e-07	9.12e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—BCHE—kidney cancer	4.32e-07	9.1e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—PTEN—kidney cancer	4.31e-07	9.08e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—GSTP1—kidney cancer	4.31e-07	9.07e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—CYP1A1—kidney cancer	4.31e-07	9.07e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—PTEN—kidney cancer	4.3e-07	9.05e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—KRAS—kidney cancer	4.29e-07	9.04e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—SLC5A5—kidney cancer	4.27e-07	8.99e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—KRAS—kidney cancer	4.24e-07	8.94e-06	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PTEN—kidney cancer	4.24e-07	8.94e-06	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—PIK3CA—kidney cancer	4.24e-07	8.93e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—PIK3CA—kidney cancer	4.22e-07	8.9e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CDKN1B—kidney cancer	4.2e-07	8.86e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ITPR2—kidney cancer	4.2e-07	8.84e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—VEGFA—kidney cancer	4.17e-07	8.8e-06	CbGpPWpGaD
Pazopanib—LYN—Immune System—PIK3CA—kidney cancer	4.13e-07	8.71e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—PIK3CA—kidney cancer	4.13e-07	8.7e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PTGS2—kidney cancer	4.13e-07	8.7e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—SLC2A1—kidney cancer	4.12e-07	8.69e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CDKN1B—kidney cancer	4.11e-07	8.67e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—IL2—kidney cancer	4.11e-07	8.67e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—MAPK3—kidney cancer	4.1e-07	8.65e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—VEGFA—kidney cancer	4.1e-07	8.64e-06	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—TP53—kidney cancer	4.1e-07	8.64e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—GSTP1—kidney cancer	4.06e-07	8.55e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—IL2—kidney cancer	4.03e-07	8.49e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CCND1—kidney cancer	4.01e-07	8.45e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—JUN—kidney cancer	4e-07	8.43e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	4e-07	8.43e-06	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—TP53—kidney cancer	3.99e-07	8.42e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CTNNB1—kidney cancer	3.97e-07	8.37e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—GSTM1—kidney cancer	3.96e-07	8.34e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MAPK3—kidney cancer	3.95e-07	8.32e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—PIK3CA—kidney cancer	3.94e-07	8.3e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CCND1—kidney cancer	3.93e-07	8.27e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—JUN—kidney cancer	3.92e-07	8.26e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—MAPK1—kidney cancer	3.9e-07	8.23e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—PIK3CA—kidney cancer	3.9e-07	8.22e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—VEGFA—kidney cancer	3.89e-07	8.2e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CTNNB1—kidney cancer	3.89e-07	8.19e-06	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PTEN—kidney cancer	3.89e-07	8.19e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—VEGFA—kidney cancer	3.88e-07	8.18e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MAPK3—kidney cancer	3.88e-07	8.17e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PTEN—kidney cancer	3.87e-07	8.16e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ABCB1—kidney cancer	3.84e-07	8.09e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MYC—kidney cancer	3.84e-07	8.09e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GSTT1—kidney cancer	3.83e-07	8.07e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ACHE—kidney cancer	3.83e-07	8.07e-06	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TP53—kidney cancer	3.81e-07	8.03e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—MAPK3—kidney cancer	3.79e-07	7.99e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PTEN—kidney cancer	3.79e-07	7.99e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MYC—kidney cancer	3.77e-07	7.95e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MAPK1—kidney cancer	3.76e-07	7.92e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CYP1A1—kidney cancer	3.75e-07	7.91e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—GSTM1—kidney cancer	3.73e-07	7.86e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MAPK1—kidney cancer	3.69e-07	7.78e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—KRAS—kidney cancer	3.69e-07	7.77e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—MYC—kidney cancer	3.69e-07	7.77e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—RAF1—kidney cancer	3.68e-07	7.76e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MAPK3—kidney cancer	3.68e-07	7.76e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MAPK3—kidney cancer	3.67e-07	7.74e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—RELA—kidney cancer	3.66e-07	7.72e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—ERBB2—kidney cancer	3.64e-07	7.68e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—SCARB1—kidney cancer	3.62e-07	7.64e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—MAPK1—kidney cancer	3.61e-07	7.6e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PTEN—kidney cancer	3.6e-07	7.58e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MTOR—kidney cancer	3.59e-07	7.57e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PTGS1—kidney cancer	3.59e-07	7.56e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MYC—kidney cancer	3.58e-07	7.54e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MYC—kidney cancer	3.57e-07	7.52e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—KRAS—kidney cancer	3.55e-07	7.48e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.54e-07	7.45e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CYP1A1—kidney cancer	3.53e-07	7.45e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PSMD7—kidney cancer	3.52e-07	7.41e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MAPK1—kidney cancer	3.5e-07	7.38e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—VEGFA—kidney cancer	3.5e-07	7.37e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MAPK1—kidney cancer	3.49e-07	7.36e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.49e-07	7.35e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—KRAS—kidney cancer	3.48e-07	7.34e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GSTP1—kidney cancer	3.44e-07	7.24e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—VEGFA—kidney cancer	3.42e-07	7.21e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—KRAS—kidney cancer	3.41e-07	7.18e-06	CbGpPWpGaD
Pazopanib—LCK—Immune System—PIK3CA—kidney cancer	3.39e-07	7.14e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CDKN1B—kidney cancer	3.37e-07	7.11e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—BCHE—kidney cancer	3.33e-07	7.03e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—KRAS—kidney cancer	3.31e-07	6.97e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MAPK3—kidney cancer	3.31e-07	6.97e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—IL2—kidney cancer	3.3e-07	6.96e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—KRAS—kidney cancer	3.3e-07	6.95e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—SLC5A5—kidney cancer	3.29e-07	6.94e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—PIK3CA—kidney cancer	3.26e-07	6.87e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ABCB1—kidney cancer	3.25e-07	6.86e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MAPK3—kidney cancer	3.24e-07	6.82e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CCND1—kidney cancer	3.22e-07	6.78e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MYC—kidney cancer	3.22e-07	6.78e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—JUN—kidney cancer	3.21e-07	6.77e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—POMC—kidney cancer	3.21e-07	6.77e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—PIK3CA—kidney cancer	3.2e-07	6.75e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CTNNB1—kidney cancer	3.19e-07	6.72e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—SLC2A1—kidney cancer	3.18e-07	6.7e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GSTM1—kidney cancer	3.16e-07	6.66e-06	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TP53—kidney cancer	3.15e-07	6.65e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MYC—kidney cancer	3.15e-07	6.64e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MAPK1—kidney cancer	3.15e-07	6.63e-06	CbGpPWpGaD
Pazopanib—LCK—Disease—PIK3CA—kidney cancer	3.13e-07	6.59e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PTEN—kidney cancer	3.11e-07	6.55e-06	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TP53—kidney cancer	3.1e-07	6.53e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MAPK1—kidney cancer	3.08e-07	6.49e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—PIK3CA—kidney cancer	3.04e-07	6.4e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—PIK3CA—kidney cancer	3.03e-07	6.39e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CYP1A1—kidney cancer	2.99e-07	6.31e-06	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PIK3CA—kidney cancer	2.99e-07	6.3e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—KRAS—kidney cancer	2.97e-07	6.26e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TP53—kidney cancer	2.94e-07	6.19e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TP53—kidney cancer	2.93e-07	6.18e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—KRAS—kidney cancer	2.91e-07	6.13e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—VEGFA—kidney cancer	2.8e-07	5.91e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—POMC—kidney cancer	2.8e-07	5.89e-06	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PIK3CA—kidney cancer	2.74e-07	5.78e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PIK3CA—kidney cancer	2.73e-07	5.75e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PIK3CA—kidney cancer	2.67e-07	5.63e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MAPK3—kidney cancer	2.65e-07	5.59e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GSTP1—kidney cancer	2.65e-07	5.59e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TP53—kidney cancer	2.64e-07	5.57e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—POMC—kidney cancer	2.64e-07	5.55e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TP53—kidney cancer	2.59e-07	5.45e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MYC—kidney cancer	2.58e-07	5.44e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PTGS2—kidney cancer	2.56e-07	5.4e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PIK3CA—kidney cancer	2.54e-07	5.35e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MAPK1—kidney cancer	2.52e-07	5.32e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ABCB1—kidney cancer	2.51e-07	5.29e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.46e-07	5.18e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GSTM1—kidney cancer	2.44e-07	5.14e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—KRAS—kidney cancer	2.38e-07	5.03e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP1A1—kidney cancer	2.31e-07	4.87e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PTEN—kidney cancer	2.23e-07	4.71e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—POMC—kidney cancer	2.23e-07	4.71e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PTGS2—kidney cancer	2.23e-07	4.7e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PIK3CA—kidney cancer	2.19e-07	4.62e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TP53—kidney cancer	2.12e-07	4.47e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PTGS2—kidney cancer	2.1e-07	4.43e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PTEN—kidney cancer	1.95e-07	4.1e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PTEN—kidney cancer	1.83e-07	3.86e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PTGS2—kidney cancer	1.78e-07	3.75e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—POMC—kidney cancer	1.72e-07	3.63e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CA—kidney cancer	1.58e-07	3.32e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PTEN—kidney cancer	1.55e-07	3.27e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PTGS2—kidney cancer	1.37e-07	2.9e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CA—kidney cancer	1.37e-07	2.89e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CA—kidney cancer	1.29e-07	2.73e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PTEN—kidney cancer	1.2e-07	2.53e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CA—kidney cancer	1.1e-07	2.31e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CA—kidney cancer	8.45e-08	1.78e-06	CbGpPWpGaD
